October 18, 2011
Forest Laboratories, Inc. Reports Fiscal Year Second Quarter 2012 Earnings Per Share of $0.91

July 19, 2011
Forest Laboratories, Inc. Reports Fiscal Year First Quarter 2012 Earnings Per Share of $0.90 Including a $0.14 Charge for a New Product Licensing Fee

April 19, 2011
Forest Laboratories, Inc. Reports Fiscal Year Fourth Quarter 2011 Earnings Per Share of $1.12

November 10, 2010
Forest Laboratories, Inc. Announces Executive Management Promotions and Retirement of Lawrence Olanoff as President and Chief Operating Officer

October 29, 2010
Forest Announces FDA Approval of Teflaro(TM) (ceftaroline fosamil) for the Treatment of Community-Acquired Bacterial Pneumonia and Acute Bacterial Skin and Skin Structure Infection

September 07, 2010
FDA Advisory Committee Recommends Approval of Forest Laboratories' Ceftaroline Fosamil for the Treatment of Community Acquired Bacterial Pneumonia and Complicated Skin and Skin Structure Infections

April 20, 2010
Forest Laboratories, Inc. Reports Fiscal Year Fourth Quarter 2010 Earnings Per Share of $0.07, Including a One-Time Charge Totaling $0.76 Per Share

January 19, 2010
Forest Laboratories, Inc. Reports Fiscal Third Quarter 2010 Earnings Per Share of $0.69, Including One-Time Charges Totaling $0.28 Per Share

December 23, 2009
Forest Laboratories Announces Acquisition of Additional Rights Related to NXL 104, a Novel Broad-Spectrum Beta-Lactamase Inhibitor

October 20, 2009
Forest Laboratories, Inc. Reports Fiscal Second Quarter 2010 Earnings Per Share of $0.61, Including a Net $0.24 Per Share Charge for One-Time Items

September 12, 2009
Forest Laboratories Presents Analysis of Two Positive Pivotal Phase III Studies of Ceftaroline for the Treatment of Community-Acquired Pneumonia (CAP) at ICAAC

August 12, 2009
Forest Laboratories and AstraZeneca to Co-Develop and Commercialize a Late Stage Next Generation Anti-Infective

June 19, 2009
Forest Laboratories Announces Positive Top-line Data from Two Pivotal Phase III Trials of Ceftaroline for the Treatment of Community-acquired Bacterial Pneumonia (CABP) Requiring Hospitalization

April 21, 2009
Forest Laboratories, Inc. Reports Fiscal Year 2009 Fourth Quarter Reported EPS of $0.31 Including $0.45 Per Share Charge Related to the Ongoing United States Attorney's Office Investigation

October 27, 2008
Positive Study Results for Ceftaroline Phase III Clinical Study for the Treatment of Complicated Skin and Skin Structure Infections Presented at ICAAC / IDSA

June 19, 2008
Forest Laboratories Announces Positive Results from Phase III Clinical Studies of Ceftaroline for the Treatment of Complicated Skin and Skin Structure Infections

April 15, 2008
Forest Laboratories, Inc. Reports Fiscal Year 2008 Fourth Quarter Reported EPS of $0.55 Including $0.35 Per Share Charge for Licensing Payment

January 22, 2008
Novexel and Forest Laboratories Announce License Agreement for NXL 104, a Novel Broad-Spectrum Beta Lactamase Inhibitor

April 24, 2007
Forest Laboratories, Inc. Reports Fiscal Year 2007 Fourth Quarter Revenues of $885,000,000, Reported EPS Loss of ($0.75) and Adjusted EPS of $0.74*, Excluding the Effect of the Cerexa Acquisition

January 16, 2007
Forest Laboratories, Inc. Reports Q3'07 Diluted Earnings Per Share of $0.78

January 11, 2007
Forest Laboratories Announces Completion of Acquisition of Cerexa, Inc.

December 14, 2006
Forest Laboratories Announces Acquisition of Cerexa, Inc.